214 related articles for article (PubMed ID: 12384557)
1. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.
Collingridge DR; Carroll VA; Glaser M; Aboagye EO; Osman S; Hutchinson OC; Barthel H; Luthra SK; Brady F; Bicknell R; Price P; Harris AL
Cancer Res; 2002 Oct; 62(20):5912-9. PubMed ID: 12384557
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
[TBL] [Abstract][Full Text] [Related]
6. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
7. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
Asano M; Yukita A; Matsumoto T; Hanatani M; Suzuki H
Hybridoma; 1998 Apr; 17(2):185-90. PubMed ID: 9627059
[TBL] [Abstract][Full Text] [Related]
8. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
9. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins.
Halin C; Niesner U; Villani ME; Zardi L; Neri D
Int J Cancer; 2002 Nov; 102(2):109-16. PubMed ID: 12385005
[TBL] [Abstract][Full Text] [Related]
11. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
15. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
[TBL] [Abstract][Full Text] [Related]
16. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
[TBL] [Abstract][Full Text] [Related]
17. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.
Haslmayer P; Thalhammer T; Jäger W; Aust S; Steiner G; Ensinger C; Obrist P
Int J Oncol; 2002 Oct; 21(4):915-20. PubMed ID: 12239635
[TBL] [Abstract][Full Text] [Related]
19. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
Filleur S; Courtin A; Ait-Si-Ali S; Guglielmi J; Merle C; Harel-Bellan A; Clézardin P; Cabon F
Cancer Res; 2003 Jul; 63(14):3919-22. PubMed ID: 12873985
[TBL] [Abstract][Full Text] [Related]
20. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
